Pharmaceutical Sourcing and Onshoring Survey – 2022 Edition

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Recent geopolitical events are causing the pharma industry to consider its supply chain more carefully than ever. Highly developed pharma markets rely on foreign suppliers for their drugs, especially China and India. The COVID-19 pandemic, rising raw material and fuel costs, Russia’s war against Ukraine, and other events are prompting industry conversations about drug shortages and supply chain security.

The pharmaceutical sourcing and onshoring survey report assess the outlook for pharmaceutical supply chains over the next 12 months to determine to what extent bio/pharmaceutical companies and their service providers are concerned, and whether they plan to “onshore” or “offshore” their manufacturing steps.

Key Findings of Pharmaceutical Onshoring Survey

Most companies surveyed do not have onshoring plans and will maintain the same onshoring/offshoring balance. However, onshoring plans are more popular than offshoring. European companies are more likely to onshore than North American companies.

Onshoring plans are similar despite more API currently being made abroad than dosage. Client demand, cost of goods and labor, and geopolitical concerns influence API sourcing while supply chain security, client demand, and quality influence dose/packaging decisions.

Pharmaceutical Industry Value Chain

The key value chains of the pharmaceutical industry are active pharmaceutical ingredients (API), followed by dose, and packaging.

API Onshoring Plans by Geography

Three regions were considered for the API sourcing and onshoring survey. They were North America, Europe, and APAC. More than 20% of the respondents in North America were willing to shift a greater proportion of the API manufacturing to the headquarters country or main countries where the clients operate. More than 40% of the clients believed that onshoring supply chains will make them more secure.

Onshoring Plans by Drug Types

Small molecule drugs were the most popular for onshoring. US politicians have emphasized onshoring more advanced/complex molecules. Innovator drugs are more popular for onshoring in North America while generic drugs are more popular for onshoring in Europe. Orphan and COVID-19 drugs are the other popular choices for onshoring.

To know more about the pharmaceutical sourcing and onshoring survey, download a free report sample

Pharmaceutical Sourcing and Onshoring Survey Report Overview

Key Value Chains Active Pharmaceutical Ingredient (API), Dose, and Packaging
Key Geographical Regions North America, Europe, and APAC



This report provides:

  • Overview of supply chain trends and key stakeholders’ attitudes to onshoring and sourcing
  • Detailed survey of industry plans to change sourcing strategy
  • Analysis by geography, drug molecule type, company type, and manufacturing step

Reasons to Buy

This report is required reading for:

  • CMO executives who must have a deep understanding of the pharmaceutical supply chain to make strategic planning and investment decisions.
  • Sourcing and procurement executives must understand crucial components of the supply base in order to make decisions about supplier selection and management.
  • Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Table of Contents

About GlobalData

Study Design

Respondent Mix

The Onshoring Question

Other Supply Chain Challenges

Key Findings


Contact Us


Survey Respondent Mix: Company Geography

Respondent Mix by Seniority Level

Respondent Mix by Company Size

Respondent Mix by Company’s Business Type

Respondent Mix by Drug Portfolio

The Pharma Supply Chain

Supply Chain Evolution for API Over the Next 12 Months

Reasons for Onshoring API Over the Next 12 Months

Supply Chain Evolution for Finished Dose and Packaging Over the Next 12 Months

Reasons for Onshoring Dose/Packaging Over the Next 12 Months

FDA-Registered Facilities

Onshoring Plans – by Drug Type (1)

Onshoring Plans – by Drug Type (2)

Onshoring – Will It Work? (1)

Onshoring – Will It Work? (2)

Challenges for the Next 12 Months – by Company Geography

Challenges for the Next 12 Months – by Company Business Model

Key Findings

Frequently asked questions

Pharmaceutical Sourcing and Onshoring Survey – 2022 Edition standard reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Pharmaceutical Sourcing and Onshoring Survey – 2022 Edition was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Pharmaceutical Sourcing and Onshoring Survey – 2022 Edition in real time.

  • Access a live Pharmaceutical Sourcing and Onshoring Survey – 2022 Edition dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.